News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
6,336 Results
Type
Article (754)
Press Release (5582)
Section
Business (1799)
Career Advice (4)
Deals (404)
Drug Delivery (4)
Drug Development (702)
Employer Resources (1)
FDA (260)
Job Trends (157)
News (3640)
Policy (817)
Tag
Academia (10)
Alliances (362)
Alzheimer's disease (2)
Approvals (256)
Artificial intelligence (1)
Autoimmune disease (1)
Bankruptcy (5)
Best Places to Work (71)
Biosimilars (32)
Cancer (1)
Career advice (4)
Cell therapy (1)
Clinical research (616)
Collaboration (4)
Complete response letters (1)
COVID-19 (18)
C-suite (1)
Data (12)
Denatured (3)
Diabetes (1)
Diagnostics (7)
Diversity, equity & inclusion (1)
Drug pricing (7)
Earnings (662)
Employer resources (1)
Events (496)
Executive appointments (9)
FDA (260)
GLP-1 (8)
Government (95)
Healthcare (67)
Immunology and inflammation (6)
Infectious disease (18)
Inflammatory bowel disease (10)
Inflation Reduction Act (1)
IPO (82)
IRA (2)
Job creations (87)
Job search strategy (4)
Layoffs (17)
Legal (454)
Medical device (20)
Medtech (20)
Mergers & acquisitions (320)
Metabolic disorders (1)
Multiple sclerosis (3)
Neuroscience (11)
NextGen: Class of 2025 (42)
Non-profit (8)
Northern California (12)
Obesity (1)
Opinion (8)
Patents (4)
People (691)
Pharmacy benefit managers (2)
Phase I (75)
Phase II (184)
Phase III (345)
Pipeline (9)
Podcasts (3)
Policy (3)
Postmarket research (69)
Preclinical (29)
Prostate cancer (1)
Radiopharmaceuticals (1)
Rare diseases (1)
Real estate (31)
Regulatory (290)
Research institute (9)
Schizophrenia (6)
Southern California (6)
Startups (28)
United States (63)
Vaccines (1)
Weight loss (1)
Women's health (1)
Date
Last 7 days (3)
Last 30 days (15)
Last 365 days (243)
2025 (41)
2024 (265)
2023 (240)
2022 (815)
2021 (584)
2020 (462)
2019 (329)
2018 (328)
2017 (378)
2016 (330)
2015 (516)
2014 (310)
2013 (280)
2012 (259)
2011 (251)
2010 (217)
Location
Africa (12)
Arizona (1)
Asia (1776)
Australia (57)
California (17)
Canada (5)
Connecticut (1)
Delaware (1)
Europe (983)
Florida (5)
Illinois (2)
Massachusetts (8)
Minnesota (1)
Missouri (1)
New Jersey (16)
New York (3)
North Carolina (1)
Northern California (12)
Pennsylvania (2)
Rhode Island (1)
South America (12)
Southern California (6)
Washington D.C. (3)
Wisconsin (1)
6,336 Results for "teva".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue
Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.
November 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Teva Releases Q1 2025 Aide Memoire
March 28, 2025
·
2 min read
Legal
Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations
The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred prosecution agreement.
October 11, 2024
·
2 min read
·
Tristan Manalac
Multiple sclerosis
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since December 1996 and six patient deaths.
January 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
March 31, 2025
·
20 min read
Press Releases
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
March 3, 2025
·
2 min read
Business
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.
May 15, 2024
·
7 min read
Press Releases
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
March 28, 2025
·
2 min read
Press Releases
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
February 24, 2025
·
21 min read
Press Releases
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 6, 2024
·
4 min read
1 of 634
Next
